BCHE and Alzheimer disease: Even though Tacrine-SPRC was synthesized aiming to develop a hybrid molecule between a native drug and a natural antioxidant compound, SPRC could be classified as a H2S-releasing agent, thus leading us to consider Tacrine-SPRC as promising scaffold for the development of new H2S-releasing/cholinesterase inhibitor drugs for AD therapy.